Immunotherapy approved that lets many rectal cancer patients skip surgery
Published
FDA gave accelerated approval to GSK's Jemperli (dostarlimab) for adults with stage II or III rectal cancer that has a specific genetic feature called dMMR or MSI-H. In the main study, about 7 in 10 patients needed no surgery, chemo or radiation after treatment. A tumor test shows whether you qualify.
Source: The ASCO Post
This is a plain-language summary. Read the original source for full details.